文献リスト

1) Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res. 2007; 37 Suppl 2: S95-100

2) Bieche I, Asselah T, Laurendeau I, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology. 2005; 332: 130-44

3) Honda M, Yamashita T, Ueda T, et al. Different signaling pathways in the liver of patients with chronic hepatitis B or chronic hepatitis C. Hepatology. 2006; 44: 1122-38

4) Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007; 45: 938-47

5) Budhu A, Chen Y, Kim JW, et al. Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins. Carcinogenesis. 2007; 28: 1552-60

6) Smith MW, Walters KA, Korth MJ, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology. 2006; 130: 179-87

7) Uno K, Suginoshita Y, Kakimi K, et al. Impairment of IFN-α production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 7330-4

8) Kudo M, Sakaguchi Y, Chung H, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007; 72 Suppl 1: 132-8

9) Yano H, Ogasawara S, Momosaki S, et al. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006; 26: 964-75

10) Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res. 2006; 34: 65-73

11) Farinati F, Cardin R, Bortolami M, et al. Hepatitis C virus: from oxygene free radicals to hepatocellular carcinoma. J Viral Hepat. 2007; 14: 821-9

12) Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated carcinogenesis. Cancer Res. 2001; 61: 4365-70

13) Korenaga M, Wang T, LiY, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. Gastroenterology. 2005; 280: 37481-8

14) Cardin R, Saccoccio G, Masutti F, et al. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: Validation in an open population study. J Hepatol. 2001; 34: 587-92

15) Tanaka H, Fujita N, Sugimoto R, et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer. 2008; 98: 580-6

16) Fujita N, Horiike S, Sugimoto R, et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med. 2007; 42: 353-62

17) Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007; 13(1-2): 97-104

18) Nagashima M, Kudo M, Chung H, et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res. 2006; 36: 288-93

19) Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008; 134: 226-38

20) Vidali M, Tripodi MF, Ivaldi A, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol. 2008; 48: 399-406

21) Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008; 134: 1699-714

22) Sheikh MY, Choi J, Qadri I, et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 2008; 47: 2127-33

23) Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A. 2007; 104: 1661-6

24) Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008; 118: 683-94

25) Jonsson JR, Barrie HD, O'Rourke P, et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology. 2008; 48: 80-7

26) Kurosaki M, Matsunaga K, Hirayama I, et al. The presence of steatosis and elevation of aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol. 2008; 48: 736-42

27) Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004; 126: 840-8

28) Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology. 2006; 130: 2087-98

29) Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003; 97: 3036-43

30) Pekow JR, Bhan AK, Zheng H, et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer. 2007; 109: 2490-6

31) Takuma Y, Nouso K, Makino Y, et al. Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. Liver Int. 2007; 27: 620-6

32) Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005; 54: 533-9

33) Komura T, Mizukoshi E, Kita Y, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol. 2007; 102: 1939-46

34) Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008; 47: 1856-62

35) Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008; 135: 111-21

36) Ikeda K. Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C. Hepatol Res. 2007; 37 Suppl 2: S287-93

37) Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007; 42: 830-6

38) Kobayashi M, Ikeda K, Arase Y, et al. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol. 2008; 43: 63-70

39) Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006; 131: 1758-67

40) Nishida N, Nagasaka T, Nishimura T, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008; 47: 908-18

41) Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006; 25: 3834-47

42) Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007; 46: 48-57

43) Bortolami M, Cardin R, Kotsafti A, et al. TGF-beta and hepatocellular carcinoma. Hepatology. 2008; 47: 1095-6

44) Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008; 48: 83-90

45) Sato Y, Kato J, Takimoto R, et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut. 2006; 55: 1801-8

46) Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007; 9: 1089-97

47) Kumar D, Farrell GC, Kench J, et al. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005; 20: 1395-400

48) Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999; 131: 174-81

49) Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008; 135: 821-9

50) Ikeda K, Arase Y, Saitoh S, et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. Intervirology. 2006; 49(1-2): 82-90

51) Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44: 1543-54

52) 永木正仁, 清水雅仁, 森脇久隆. レチノイドによる肝癌再発抑制. 日本消化器病学会雑誌. 2008; 105: 802-7

53) Ohno T, Tanaka Y, Sugauchi F, et al. Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. Hepatol Res. 2008; 38: 683-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp